Results 221 to 230 of about 185,906 (291)

Current Evidence on IL-17 and IL-(12)/23 Inhibitor Safety during Pregnancy in Psoriasis: A Call for Harmonized Data Collection. [PDF]

open access: yesActa Derm Venereol
Barenbrug L   +5 more
europepmc   +1 more source

Dipeptidyl Peptidase‐4 Inhibitor Use and Risk of Pemphigus Vulgaris and Foliaceus: A Retrospective Cohort Study Using Databases of the Korea National Health Insurance Claims and the National Health Screening Examination

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Although population‐based studies have reported an increased risk of bullous pemphigoid and pemphigus associated with dipeptidyl peptidase‐4 (DPP‐4) inhibitors, there is limited, well‐designed epidemiological evidence for pemphigus vulgaris (PV), which has only been supported by case reports thus far.
Jaein Lee, Jae Hyun Bae, Seokyung Hahn
wiley   +1 more source

Educational Artificial Intelligence Software to Support Assessment of Atopic Dermatitis Severity

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Accurate assessment of the severity of atopic dermatitis is crucial for guiding treatment. However, the Eczema Area and Severity Index (EASI), a widely used clinical assessment tool, relies on subjective visual scoring, which can lead to inter‐rater variability. This study aimed to evaluate the performance of convolutional neural network‐based
Kenichi Yamanaka   +6 more
wiley   +1 more source

The Impact of Molluscum Contagiosum on Depression, Anxiety and Quality of Life in Children

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT This study aimed to compare depressive symptoms, anxiety symptoms, and health‐related quality of life between children with molluscum contagiosum and healthy controls and to examine whether lesion number and anatomical localization were associated with these outcomes. This prospectively conducted cross‐sectional study included 72 children with
Abdulbaki Artik   +10 more
wiley   +1 more source

Real‐World Effectiveness, Treatment Course, and Safety of Tapinarof Cream 1% for Atopic Dermatitis and Plaque Psoriasis in Japan

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Background Tapinarof cream 1%, a non‐steroidal topical aryl hydrocarbon receptor‐modulating agent, is approved in Japan for atopic dermatitis (AD) and plaque psoriasis. Real‐world data on longitudinal outcomes, treatment continuation, interruption and restart, and adverse‐event timing are limited. Methods This single‐center retrospective study
Kanade Iino   +2 more
wiley   +1 more source

Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Systemic treatments for moderate‐to‐severe plaque psoriasis have been advanced from broad immunosuppressants up to agents more selectively targeting cytokines, cytokine receptors, or intracellular signaling. The current systemic treatments mainly consist of conventional systemic agents, biologics targeting tumor necrosis factor (TNF)‐α ...
Teppei Hagino, Naoko Kanda
wiley   +1 more source

Home - About - Disclaimer - Privacy